Lead Compass News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Evotec invests into Oxford Cell Therapy Company OxVax Search jobs Evotec invests into Oxford Cell Therapy Company OxVax Evotec is co-leading investment into OxVax, a spinout from Oxford University, which is formed with the objective of producing first-in-class cancer vaccines.  Hamburg, Germany, 21 April 2021: Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has invested into OxVax, a new immuno-oncology company based on research from Oxford University, which enables the development of the next generation of cancer vaccines with the potential to overcome the limitations of the current approaches. OxVax is developing an innovative cancer vaccine platform based on a unique and proprietary population of dendritic cells capable of inducing a potent anti-tumour immune response. The company s technology allows the bulk manufacture of these cells from donor blood derived stem cells. By ex vivo lo

Thomas hankeMarcelo bravoPaulj fairchildTim daviesEvotec se frankfurt stock exchangeOxford universityFrankfurt stock exchangeProfessor paulj fairchildSir william dunn schoolChief executive officerSouth korean basedLead compassAcademic partnershipsAssociate professorStem cellsChief executive